Interpace Bioscience News Today

 ●Q3 Revenue of $9.1 million; an 11% increase year-over-year ●Q3 Test volume up 11% year-over-year ●Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial...

PARSIPPANY, NJ, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial...

PARSIPPANY, NJ, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”) a leader in enabling...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Interpace Biosciences Announces First Quarter 2021 Financial and Business Results Interpace Biosciences, Inc.May 11, 2021 GMT   ● Q1 Revenue of $9.8 Million is Company’s Highest as Combined Molecular Diagnostics and Pharma Services Business       ADVERTISEMENT PARSIPPANY, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today...

Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR March 17, 2021 07:30 ET | Source: Interpace Biosciences, Inc. Interpace Biosciences, Inc. Part of Company’s Site Consolidation and Cost Savings Measures Parsippany, NJ, March 17, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTC: IDXG) announced today that it has entered into a definitive agreement to sell its New Haven CT CLIA certified, CAP accredited laboratory to DiamiR Bioscien...

DiamiR Announces Acquisition of CLIA Lab from Interpace Biosciences News provided by Share this article Share this article MONMOUTH JUNCTION, N.J., March 17, 2021 /PRNewswire/ -- DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that it has entered into a definitive agreement to acquire a CLIA (Clinical Laboratory Improvement Amendments) certified laboratory in New Haven, CT from Interpace Biosciences, Inc. Subject to specific te...

Dear Shareholders, As the newly appointed President and CEO of Interpace I want to take a moment to formally introduce myself and share the new vision and mission for this Company as it relates to our core capabilities, growth prospects and directional outlook for this year and beyond. I joined Interpace with significant leadership experience, including with several specialty clinical laboratories. This includes serving as President & CEO of Boston Heart Diagnostics, Viracor-IBT Laboratories ...

Interpace Biosciences Announces CFO Leadership Transition February 04, 2021 16:42 ET | Source: Interpace Biosciences, Inc. Interpace Biosciences, Inc. UNITED STATES PARSIPPANY, NJ, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, announced today that its Board of Directors has appointed Tom Freeburg, Chief Accounting Officer, as Interpace’s Chief Financial ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital Interpace Biosciences, Inc.February 1, 2021 GMT Parsippany, NJ, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) announced today that it has executed a license agreement with Rutgers, The State University of New Jersey, and Massachusetts General Hospital for a novel monoclon...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Interpace Biosciences Announces Third Quarter 2020 Financial and Business Results and ... Interpace Biosciences, Inc.January 20, 2021 GMT Third Quarter Net Revenue of $8.2 Million Up 7% vs Prior Year; Third Quarter Year to Date Net Revenue of $22.8 Million Up 14% vs Prior Year Estimates Fourth Quarter Net Revenue range of $9.0 million - $10.0 million Realized Reimbursement on Higher ThyGeNEXT Pricing ...